A randomized phase II clinical trial to evaluate the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with CLDN18.2-positive unresectable advanced/recurrent gastric/esophagogastric junction/esophageal adenocarcinoma (GENTLE-Z study)
Latest Information Update: 23 Jun 2025
At a glance
- Drugs Zolbetuximab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms GENTLE-Z
Most Recent Events
- 23 Jun 2025 New trial record